Sign inCreate account

Report workspace tools

NCT00535132COMPLETEDanonymous

A Blinded-initiation Study of Medication Satisfaction in Subjects With Schizophrenia Treated With Paliperidone ER After Suboptimal Response to Oral Risperidone

Sponsor

Source record

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase

Source record

PHASE4

Modality

AI-normalized

small molecule

Target

AI-normalized

Oral Risperidone, Paliperidone ER

Indication / condition

AI-normalized

Schizophrenia

Intervention

Source record

Oral Risperidone, Paliperidone ER

Source & freshness

Source record

NCT ID

NCT00535132

Original source

ClinicalTrials.gov

Source last updated

May 09, 2014

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00535132

Title

A Blinded-initiation Study of Medication Satisfaction in Subjects With Schizophrenia Treated With Paliperidone ER After Suboptimal Response to Oral Risperidone

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Status

COMPLETED

Phase

PHASE4

Condition raw

Schizophrenia

Condition normalized

Schizophrenia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Oral Risperidone, Paliperidone ER

Target normalized

Oral Risperidone, Paliperidone ER

Interventions

Oral Risperidone, Paliperidone ER

Public preview

Source record

The purpose of this study is to evaluate medication satisfaction after at least 4 weeks of paliperidone ER (extended-release), an antipsychotic, treatment in patients with schizophrenia who were previously taking either 4 or 6 mg of risperidone daily by mouth, but who are not satisfied with their treatment.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Blinded-initiation Study of Medication Satisfaction in Subjects With Schizophrenia Treated With Paliperidone ER After Suboptimal Response to Oral Risperidone

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00535132

Status

COMPLETED

Phase

PHASE4

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Executive brief

Investment-Ready Snapshot

The purpose of this study is to evaluate medication satisfaction after at least 4 weeks of paliperidone ER (extended-release), an antipsychotic, treatment in patients with schizophrenia who were previously taking either 4 or 6 mg of risperidone daily by mouth, but who are not satisfied with their treatment.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 09, 2014
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00535132

Indication

Schizophrenia

Modality

small molecule

Target

Oral Risperidone, Paliperidone ER

Intervention

Oral Risperidone, Paliperidone ER

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.